Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist

International Journal of Clinical Oncology

Volumn 6, Issue 1, 2001, Pages 29-33

  Noguchi, K ^a   Uemura, H ^a   Harada, M ^b   Miura, T ^b   Moriyama, M ^c   Fukuoka, H ^d   Kitami, K ^e   Hosaka, M ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c AKITA UNIVERSITY   (Japan)

^d Yokohama Minami Kyosai Hospital   (Japan)

^e International Goodwill Hospital   (Japan)

Author keywords

Flutamide; LH RH agonist; Prostate cancer; PSA flare

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; GUANOSINE TRIPHOSPHATE; LACTATE DEHYDROGENASE; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; HUMAN; LEUKOPENIA; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA;

EID: 0035079493     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012076     Document Type: Article

References (17)

1. 6-LH-RH analogue in patients with metastatic prostatic cancer
2. Importance of early tumour exacerbation in patients treated with long-acting analogues of gonadotrophin-releasing hormone for advanced prostatic cancer
3. Tumor flare in hormonal therapy
4. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue induced testosterone surge in patients with metastatic carcinoma of the prostate
5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
6. Causes of prostatic tumor flare during treatment with LH-RH agonist analogs
7. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate
8. Oestrogen pre-treatment abolishes luteinizing hormone-releasing hormone testosterone stimulation
9. Luteinizing hormone-releasing hormone agonists in prostate cancer
10. Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate
11. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for 2 weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients
12. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
13. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
14. Inhibition of disease flare with flutamide in combined androgen blockade for prostate cancer patients
15. Histological and endocrinological studies on prostatic carcinoma
16. Do the worst histological elements in needle biopsy specimens of prostate cancer predict prognosis?
17. The flare in serum alkaline phosphatase activity after orchiectomy: A valuable negative prognostic index for progression-free survival in prostatic carcinoma